Find the correct name of the new-generation drug used in drug-eluting stents from the below-mentioned hints. Hints: It is a highly lipophilic analog of the first-generation drug sirolimus. It has a shorter in vivo half-life than sirolimus. The USFDA approved a drug-eluting coronary stent system in 2021, which employs this drug as an antiproliferative agent.
Sources : FDA, European Cardiology Review ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no warranties, explicit or implied, about the suitability, reliability, or adequacy of the information, including data visualization elements and graphics. We do not endorse any medical treatment, product, ideas or service, including the content from our industry partners. We do not associate with the views of any individual, community, organization,…
